Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antimutagenic effects in humans.

M L Mendelsohn1

  • 1Biomedical Sciences Division, University of California, Lawrence Livermore National Laboratory 94550.

Mutation Research
|June 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Morphological analysis of cells and chromosomes by digital computer.

Methods of information in medicine·2011
Same author

Evaluation of three somatic genetic biomarkers as indicators of low dose radiation effects in clean-up workers of the Chernobyl nuclear reactor accident.

Radiation protection dosimetry·2002
Same author

A model for radiation-related cancer suggested by atomic bomb survivor data.

Radiation research·1999
Same author

Twelfth Aspen Cancer Conference: mechanisms of toxicity and carcinogenesis.

Molecular carcinogenesis·1998
Same author

Case-control study of malignant melanoma among employees of the Lawrence Livermore National Laboratory.

American journal of industrial medicine·1997
Same author

Somatic cell mutation as a radiation biodosimeter and predictor of cancer risk and aging.

Japanese journal of cancer research : Gann·1996
Same journal

Monoallelic germline RAD51C, RAD51D, and BRIP1 variants in hereditary cancer testing: Variant spectrum and clinical counselling implications.

Mutation research·2026
Same journal

Prediction of hepatocellular carcinoma associated biomarkers in TP53 gene; A comprehensive in silico analysis.

Mutation research·2026
Same journal

IDH1 mutation promotes angiogenesis via upregulation of hypoxia inducible factor 1 alpha in glial tumors.

Mutation research·2026
Same journal

Targeting overexpressed oncogenes in esophageal cancer through miRNA-mediated gene silencing: Insights from binding affinity and thermodynamic profiling.

Mutation research·2026
Same journal

The active compound quercetin from Polygonum cuspidatum targets COL3A1 to enhance CD8⁺ T cell cytotoxicity in gastric cancer.

Mutation research·2026
Same journal

E2F1 promotes LIHC malignant phenotype via NEK2-mediated Wnt/β-catenin and Notch activation and EMT.

Mutation research·2026
See all related articles

Antimutagenicity studies can now assess human somatic mutation using established assays. Future research should explore interventions targeting newly formed mutations to reduce cancer risk.

Area of Science:

  • Human toxicology
  • Somatic mutation research
  • Antimutagenesis

Background:

  • Human somatic mutation can be measured in lymphocytes and erythrocytes using five assay-gene combinations.
  • Established methods define background mutation levels and mutagenic responses.

Purpose of the Study:

  • To discuss the application of antimutagenicity studies to human somatic mutation.
  • To highlight the potential for future research in this area.

Main Methods:

  • Utilizing five assay-gene combinations for measuring human somatic mutation.
  • Defining human background mutation levels and responses to mutagens.

Main Results:

  • Established background levels for human somatic mutation.

Related Experiment Videos

  • Demonstrated clear responses of mutant frequency to various mutagens.

    • Conclusions:

    • Antimutagenicity testing on background mutation frequencies is feasible but not yet performed.
    • A key challenge is the unknown age of mutant cells, as only newly formed mutants are susceptible to antimutagenic treatments.
    • Future studies should consider intervention strategies for active mutagenicity and other genotoxicity endpoints.